Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC)

被引:0
|
作者
Guo, Jhe-Cyuan
Lin, Chia-Chi
Huang, Ta-Chen
Chang, Chun-Jung
Kuo, Hung-Yang
Hsu, Chih-Hung
机构
[1] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
28
引用
收藏
页数:2
相关论文
共 50 条
  • [41] The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
    Brinch, Charlotte Margareta
    Hogdall, Estrid
    Junker, Niels
    Moeller, Holger Jon
    Sandfeld-Paulsen, Birgitte
    de Heer, Pieter
    Penninga, Luit
    Rossen, Philip Blach
    Krarup-Hansen, Anders
    Aggerholm-Pedersen, Ninna
    CANCERS, 2022, 14 (23)
  • [42] Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
    Khunger, Monica
    Hernandez, Adrian V.
    Pasupuleti, Vinay
    Rakshit, Sagar
    Pennell, Nathan A.
    Stevenson, James
    Mukhopadhyay, Sanjay
    Schalper, Kurt
    Velcheti, Vamsidhar
    JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 15
  • [43] Expression patterns and clinical significance of PD-L1 and PD-1 in squamous cell carcinoma of cervix
    Mendoza, R.
    Zhou, Y. Y.
    Salman, B.
    Gupta, R.
    Kanis, M. J.
    Lee, Y. C.
    Lee, W. C.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 52 - 53
  • [44] Programmed-cell death ligand 1 (PD-L1) expression in equine sarcoids and squamous cell carcinoma
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    OPEN VETERINARY JOURNAL, 2024, 14 (06) : 1476 - 1482
  • [45] Programmed Deathl (PD-1) Receptor/PD-1 Ligand (PD-L1) Expression in Fumarate Hydratase-Deficient Renal Cell Carcinoma
    Alaghehbandan, Reza
    Stehlik, Jan
    Trpkov, Kiril
    Magi-Galluzzi, Cristina
    Foix, Maria Pane
    Berney, Daniel
    Sibony, Mathilde
    Suster, Saul
    Agaimy, Abbas
    Montiel, Delia Perez
    Pivovarcikova, Kristyna
    Michalova, Kvetoslava
    Daum, Ondrej
    Ondic, Ondrej
    Rotterova, Pavia
    Michal, Michal
    Hes, Ondrej
    MODERN PATHOLOGY, 2017, 30 : 211A - 211A
  • [46] Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
    Berntsson, Jonna
    Eberhard, Jakob
    Nodin, Bjorn
    Leandersson, Karin
    Larsson, Anna H.
    Jirstrom, Karin
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [47] Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment
    Jomrich, Gerd
    Kollmann, Dagmar
    Ramazanova, Dariga
    Ristl, Robin
    Grose, Richard P.
    Ilhan-Mutlu, Ayseguel
    Preusser, Matthias
    Fassnacht, Christina
    Tsai, Yi-Chien
    Guenova, Emmanuella
    Schoppmann, Sebastian F.
    EJSO, 2022, 48 (02): : 383 - 390
  • [48] Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer (TNBC)
    Baker, T. M.
    Gatalica, Z.
    Goldstein, L. J.
    Obeid, E.
    CANCER RESEARCH, 2017, 77
  • [49] Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
    Zak, Krzysztof M.
    Kitel, Radoslaw
    Przetocka, Sara
    Golik, Przemyslaw
    Guzik, Katarzyna
    Musielak, Bogdan
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2015, 23 (12) : 2341 - 2348
  • [50] miRNA-A and programmed death ligand 1 (PD-L1) expression in oral squamous cell carcinoma
    Hyung, Hong
    Ko, Yoon Ho
    Jin, Lee Hee
    Jeon, Sang Hoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7